Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Golotimod

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Golotimod is an orally bioactive synthetic peptide containing the amino acids D-glutamine and L-tryptophan connected by a gamma-glutamyl linkage with potential immunostimulating, antimicrobial and antineoplastic activities. Golotimod has been shown to inhibit the expression of STAT-3, reversing immunosuppression and stimulating an anti-tumor immune response. It may stimulate the production of T-lymphocytes (in particular the helper T [Th1] cells), activate macrophages, and increase levels of interleukin 2 and interferon gamma.

Category

Peptide Inhibitors

Catalog number

BAT-010153

CAS number

229305-39-9

Molecular Formula

C16H19N3O5

Molecular Weight

333.34

Size	Price	Stock	Quantity
50 mg	$229	In stock

Specification
Reference Reading

IUPAC Name

(2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid

Synonyms

SCV-07; Gamma-D-Glu-L-trp; SCV07; SCV 07; Gamma-D-Glutamyl-L-tryptophan; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid

Appearance

White Solid

Purity

>98%

Sequence

H-D-gGlu-Trp-OH

Storage

Store at -20°C

Solubility

Soluble in DMSO

InChI

InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13+/m1/s1

InChI Key

CATMPQFFVNKDEY-YPMHNXCESA-N

Canonical SMILES

C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)NC(=O)CCC(C(=O)O)N

1.Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07).

Watkins B1, Pouliot K, Fey E, Tuthill C, Sonis S. Oral Dis. 2010 Oct;16(7):655-60. doi: 10.1111/j.1601-0825.2010.01671.x.

OBJECTIVE: To evaluate the efficacy of a novel immunomodulating peptide (SCV-07) in attenuating the course of radiation-induced mucositis in an established animal model of oral mucositis (OM).

2.Discontinued drugs in 2012 - 2013: hepatitis C virus infection.

Gentile I1, Buonomo AR, Zappulo E, Borgia G. Expert Opin Investig Drugs. 2015 Feb;24(2):239-51. doi: 10.1517/13543784.2015.982274. Epub 2014 Nov 11.

INTRODUCTION: Hepatitis C virus (HCV) chronically infects about 150 million people worldwide. Antiviral treatment can stop and even reverse the progression of the disease. Several antivirals have been developed. However, about 10,000 compounds are tested for each drug that eventually reaches the market. It would be useful to learn from these failures, for example, by reporting the candidate drugs that were discontinued and the reason for discontinuation.

3.SCV-07 (SciClone Pharmaceuticals/Verta).

Aspinall RJ1, Pockros PJ. Curr Opin Investig Drugs. 2006 Feb;7(2):180-5.

SciClone Pharmaceuticals and Verta are developing SCV-07, the lead in a series of immnunostimulants from Verta, for the potential treatment of tuberculosis and hepatitis C virus infection. Phase II clinical trials of the compound are ongoing.